Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Bi-specific antibody molecule inhibits tumor cell proliferation more efficiently than the two-molecule combination
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology. (Johan Rockberg)ORCID iD: 0000-0003-1096-9061
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology.ORCID iD: 0000-0002-7875-2822
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
Keyword [en]
Bispecific antibody, Her2, EGFRm gastric cancer, trastuzumab, AffiMab
National Category
Pharmaceutical Biotechnology
Identifiers
URN: urn:nbn:se:kth:diva-212926OAI: oai:DiVA.org:kth-212926DiVA: diva2:1135898
Note

QC 20170828

Available from: 2017-08-24 Created: 2017-08-24 Last updated: 2017-08-28Bibliographically approved
In thesis
1. Cell line and protein engineering tools for production and characterization of biologics
Open this publication in new window or tab >>Cell line and protein engineering tools for production and characterization of biologics
2017 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Our increasing understanding of disease mechanisms coupled with technological advances has facilitated the generation of pharmaceutical proteins, which are able to address yet unmet medical needs. Diseases that were fatal in the past can now be treated with novel biological medications improving and prolonging life for many patients. Pharmaceutical protein production is, however, a complex undertaking, which is by no means problem-free. The demand for more complex proteins and the realization of the importance of post-translational modifications have led to an increasing use of mammalian cells for protein expression. Despite improvements in design and production, the costs required for the development of pharmaceutical proteins still are far greater than those for conventional, small molecule drugs. To render such treatments affordable for healthcare suppliers and assist in the implementation of precision medicine, further progress is needed. In five papers this thesis describes strategies and methods that can help to advance the development and manufacturing of pharmaceutical proteins. Two platforms for antibody engineering have been developed and evaluated, one of which allows for efficient screening of antibody libraries whilst the second enables the straightforward generation of bispecific antibodies. Moreover, a method for epitope mapping has been devised and applied to map the therapeutic antibody eculizumab’s epitope on its target protein. In a second step it was shown how this epitope information can be used to stratify patients and, thus, contribute to the realization of precision medicine. The fourth project focuses on the cell line development process during pharmaceutical protein production. A platform is described combining split-GFP and fluorescence-activated droplet sorting, which allows for the efficient selection of highly secreting cells from a heterogeneous cell pool. In an accompanying study, the split-GFP probe was improved to enable shorter assay times and increased sensitivity, desirable characteristics for high-throughput screening of cell pools. In summary, this thesis provides tools to improve design, development and production of future pharmaceutical proteins and as a result, it makes a contribution to the goal of implementing precision medicine through the generation of more cost-effective biopharmaceuticals for well-characterized patient groups.

Place, publisher, year, edition, pages
Stockholm: KTH Royal Institute of Technology, 2017. 91 p.
Series
TRITA-BIO-Report, ISSN 1654-2312 ; 2017:16
Keyword
Pharmaceutical proteins, precision medicine, antibody engineering, epitope mapping, cell line development, split-GFP
National Category
Pharmaceutical Biotechnology
Research subject
Biotechnology
Identifiers
urn:nbn:se:kth:diva-212931 (URN)978-91-7729-497-9 (ISBN)
Public defence
2017-09-29, E3, Osquars backe 14, Stockholm, 10:00 (English)
Opponent
Supervisors
Note

QC 20170828

Available from: 2017-08-28 Created: 2017-08-24 Last updated: 2017-08-30Bibliographically approved

Open Access in DiVA

No full text

Authority records BETA

Volk, Anna-LuisaLundqvist, MagnusUhlén, MathiasRockberg, Johan

Search in DiVA

By author/editor
Volk, Anna-LuisaLundqvist, MagnusUhlén, MathiasRockberg, Johan
By organisation
Proteomics and Nanobiotechnology
Pharmaceutical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 23 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf